Response to comments by Plataki and Williams

被引:0
作者
Peter Eichacker
Charles Natanson
机构
[1] CCMD-NIH,Room 2c145
来源
Intensive Care Medicine | 2007年 / 33卷
关键词
Public Health; United States; Clinical Setting; Adult Patient; Pediatric Patient;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1489 / 1489
相关论文
共 10 条
[1]  
Warren S(2005). Risks and benefits of activated protein C treatment for severe sepsis N Engl J Med 347 1027-1030
[2]  
Suffredini AF(2005)Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-1341
[3]  
Eichacker PQ(2007)Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial Lancet 369 836-843
[4]  
Munford RS(undefined)undefined undefined undefined undefined-undefined
[5]  
Abraham E(undefined)undefined undefined undefined undefined-undefined
[6]  
Laterre F(undefined)undefined undefined undefined undefined-undefined
[7]  
Garg R(undefined)undefined undefined undefined undefined-undefined
[8]  
Nadel S(undefined)undefined undefined undefined undefined-undefined
[9]  
Goldstein B(undefined)undefined undefined undefined undefined-undefined
[10]  
Williams MD(undefined)undefined undefined undefined undefined-undefined